Search
Peter Molloy (left) and chairman William Garner founded Race Oncology in 2016 to commercialise Bisantrene. Photo: Attila Csaszar

Race challenges big pharma mindset

For many cancer sufferers, the side effects of traditional chemotherapy treatments can compound an already difficult situation.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/03/18

1 year TSR5 year TSR
163rdRace Oncology64%0%
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

11/05/17
$17k Bought
30/03/17
$4k Bought
28/03/17
$20k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

224th↓Race Oncology$0
236 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer